Verve Cost Of Revenue vs Revenue Per Share Analysis

VERV Stock

USD 5.31 0.02 0.38%

Verve Therapeutics financial indicator trend analysis is much more than just breaking down Verve Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verve Therapeutics is a good investment. Please check the relationship between Verve Therapeutics Cost Of Revenue and its Revenue Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verve Therapeutics Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have totally related.

The correlation between Verve Therapeutics' Cost Of Revenue and Revenue Per Share is 1.0. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Verve Therapeutics, assuming nothing else is changed. The correlation between historical values of Verve Therapeutics' Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Verve Therapeutics are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., Verve Therapeutics' Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Verve Therapeutics income statement and represents the costs associated with goods and services Verve Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Verve Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verve Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.At this time, Verve Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to climb to about 1.5 B in 2024, whereas Selling General Administrative is likely to drop slightly above 25.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	76K	6.9M	7.9M	8.3M
Net Interest Income	142K	6.9M	21.3M	22.4M

Interest Income Net Interest Income

Verve Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.38	0.87	1.0	0.99	0.89	0.95	0.91	0.73	-0.82	-0.92	0.64	0.89	0.92	0.73	0.89	1.0	0.95	0.86	0.99	0.54	0.83	0.94	0.72	0.99	0.9
Short Long Term Debt Total	0.38		0.44	0.39	0.26	0.62	0.3	0.5	0.5	0.01	-0.43	-0.33	0.4	0.48	0.27	0.09	0.36	0.31	0.44	0.35	0.97	0.09	0.31	0.9	0.26	0.5
Other Current Liab	0.87	0.44		0.89	0.85	0.77	0.84	0.71	0.53	-0.67	-0.82	0.61	0.78	0.74	0.7	0.92	0.89	0.88	0.66	0.91	0.55	0.93	0.82	0.7	0.85	0.71
Total Current Liabilities	1.0	0.39	0.89		0.99	0.89	0.95	0.9	0.71	-0.81	-0.92	0.64	0.89	0.91	0.72	0.91	1.0	0.95	0.84	1.0	0.54	0.85	0.94	0.72	0.99	0.89
Total Stockholder Equity	0.99	0.26	0.85	0.99		0.84	0.95	0.88	0.68	-0.85	-0.9	0.71	0.87	0.89	0.71	0.92	0.99	0.95	0.83	0.99	0.43	0.86	0.93	0.63	1.0	0.87
Other Liab	0.89	0.62	0.77	0.89	0.84		0.92	0.98	0.92	-0.76	-0.97	0.4	0.95	0.98	0.82	0.67	0.88	0.91	0.91	0.86	0.74	0.63	0.93	0.86	0.84	0.98
Net Tangible Assets	0.95	0.3	0.84	0.95	0.95	0.92		0.94	0.82	-0.92	-0.97	0.68	0.97	0.95	0.85	0.87	0.95	1.0	0.87	0.95	0.45	0.83	1.0	0.64	0.95	0.94
Property Plant And Equipment Net	0.91	0.5	0.71	0.9	0.88	0.98	0.94		0.91	-0.81	-0.96	0.43	0.95	1.0	0.77	0.68	0.89	0.92	0.91	0.88	0.63	0.62	0.95	0.77	0.88	1.0
Current Deferred Revenue	0.73	0.5	0.53	0.71	0.68	0.92	0.82	0.91		-0.77	-0.91	0.38	0.92	0.9	0.86	0.46	0.71	0.79	0.94	0.66	0.65	0.4	0.85	0.73	0.68	0.92
Net Debt	-0.82	0.01	-0.67	-0.81	-0.85	-0.76	-0.92	-0.81	-0.77		0.89	-0.84	-0.91	-0.83	-0.89	-0.8	-0.83	-0.91	-0.84	-0.81	-0.18	-0.76	-0.93	-0.38	-0.85	-0.81
Retained Earnings	-0.92	-0.43	-0.82	-0.92	-0.9	-0.97	-0.97	-0.96	-0.91	0.89		-0.62	-1.0	-0.96	-0.91	-0.79	-0.92	-0.97	-0.95	-0.9	-0.59	-0.75	-0.98	-0.75	-0.9	-0.96
Accounts Payable	0.64	-0.33	0.61	0.64	0.71	0.4	0.68	0.43	0.38	-0.84	-0.62		0.62	0.46	0.7	0.82	0.67	0.69	0.58	0.65	-0.12	0.8	0.67	0.08	0.71	0.44
Cash	0.89	0.4	0.78	0.89	0.87	0.95	0.97	0.95	0.92	-0.91	-1.0	0.62		0.95	0.94	0.76	0.89	0.96	0.94	0.86	0.56	0.72	0.98	0.71	0.87	0.95
Non Current Assets Total	0.92	0.48	0.74	0.91	0.89	0.98	0.95	1.0	0.9	-0.83	-0.96	0.46	0.95		0.79	0.71	0.91	0.94	0.91	0.89	0.61	0.65	0.96	0.76	0.89	1.0
Non Currrent Assets Other	0.73	0.27	0.7	0.72	0.71	0.82	0.85	0.77	0.86	-0.89	-0.91	0.7	0.94	0.79		0.67	0.74	0.85	0.89	0.7	0.45	0.66	0.87	0.57	0.71	0.79
Other Assets	0.89	0.09	0.92	0.91	0.92	0.67	0.87	0.68	0.46	-0.8	-0.79	0.82	0.76	0.71	0.67		0.92	0.89	0.65	0.93	0.24	0.99	0.84	0.45	0.92	0.67
Cash And Short Term Investments	1.0	0.36	0.89	1.0	0.99	0.88	0.95	0.89	0.71	-0.83	-0.92	0.67	0.89	0.91	0.74	0.92		0.95	0.85	0.99	0.52	0.86	0.94	0.71	0.99	0.89
Common Stock Total Equity	0.95	0.31	0.88	0.95	0.95	0.91	1.0	0.92	0.79	-0.91	-0.97	0.69	0.96	0.94	0.85	0.89	0.95		0.85	0.95	0.46	0.87	0.99	0.64	0.95	0.92
Common Stock Shares Outstanding	0.86	0.44	0.66	0.84	0.83	0.91	0.87	0.91	0.94	-0.84	-0.95	0.58	0.94	0.91	0.89	0.65	0.85	0.85		0.8	0.63	0.57	0.9	0.75	0.83	0.91
Short Term Investments	0.99	0.35	0.91	1.0	0.99	0.86	0.95	0.88	0.66	-0.81	-0.9	0.65	0.86	0.89	0.7	0.93	0.99	0.95	0.8		0.49	0.88	0.93	0.68	0.99	0.87
Non Current Liabilities Total	0.54	0.97	0.55	0.54	0.43	0.74	0.45	0.63	0.65	-0.18	-0.59	-0.12	0.56	0.61	0.45	0.24	0.52	0.46	0.63	0.49		0.22	0.47	0.97	0.43	0.63
Other Current Assets	0.83	0.09	0.93	0.85	0.86	0.63	0.83	0.62	0.4	-0.76	-0.75	0.8	0.72	0.65	0.66	0.99	0.86	0.87	0.57	0.88	0.22		0.8	0.41	0.86	0.61
Other Stockholder Equity	0.94	0.31	0.82	0.94	0.93	0.93	1.0	0.95	0.85	-0.93	-0.98	0.67	0.98	0.96	0.87	0.84	0.94	0.99	0.9	0.93	0.47	0.8		0.65	0.93	0.95
Total Liab	0.72	0.9	0.7	0.72	0.63	0.86	0.64	0.77	0.73	-0.38	-0.75	0.08	0.71	0.76	0.57	0.45	0.71	0.64	0.75	0.68	0.97	0.41	0.65		0.63	0.77
Net Invested Capital	0.99	0.26	0.85	0.99	1.0	0.84	0.95	0.88	0.68	-0.85	-0.9	0.71	0.87	0.89	0.71	0.92	0.99	0.95	0.83	0.99	0.43	0.86	0.93	0.63		0.87
Property Plant And Equipment Gross	0.9	0.5	0.71	0.89	0.87	0.98	0.94	1.0	0.92	-0.81	-0.96	0.44	0.95	1.0	0.79	0.67	0.89	0.92	0.91	0.87	0.63	0.61	0.95	0.77	0.87

Click cells to compare fundamentals

Verve Therapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verve Cost Of Revenue vs Revenue Per Share Analysis

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Revenue Per Share

Verve Therapeutics fundamental ratios Correlations

Verve Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Verve Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Current Liabilities
Short Term Investments	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Common Stock Total Equity	+ 1.0	Net Tangible Assets

Cash	- 1.0	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Net Tangible Assets
Retained Earnings	- 0.97	Other Liab
Property Plant And Equipment Gross	- 0.96	Retained Earnings